Progesterone Capsule
Product Images NDC 70700-162

4 FDA label images from Xiromed, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Progesterone (NDC 70700-162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label-100mg-100ct-bottle-jpg (Xiromed Prog Caps Label 100 mg)

Label-100mg-100ct-bottle-jpg (Xiromed Prog Caps Label 100 mg)
Packaging label for Progesterone Capsules 100 mg, oral capsules. The label includes warnings such as 'DO NOT USE IF ALLERGIC TO PEANUTS' and instructions to dispense the patient information leaflet separately. It indicates that each capsule contains micronized progesterone 100 mg. The label also includes storage instructions, manufacturer details (Xiromed, LLC, Florham Park, NJ), and package count of 100 capsules. There is a barcode and NDC number 70700-1620-1.*
FDA Label Image

Label-200mg-100ct-bottle-jpg (Xiromed Prog Caps Label 200 mg)

Label-200mg-100ct-bottle-jpg (Xiromed Prog Caps Label 200 mg)
Label for Progesterone Capsules 200 mg by Xiromed, LLC. The container holds 100 oral capsules with micronized progesterone. Warnings include avoiding use if allergic to peanuts and instructions to dispense the patient information leaflet separately. Storage advises controlled room temperature and protection from moisture. The product is made in Spain and China as stated.*
FDA Label Image

Chemical Structure (Xiromed Prog Structure)

Chemical Structure (Xiromed Prog Structure)
Chemical structure of Progesterone, showing the molecular arrangement of atoms and bonds characteristic of this hormone.*
FDA Label Image

Figure 1 (Xiromed Figure 1)

Figure 1 (Xiromed Figure 1)
A Kaplan-Meier curve showing the probability of hyperplasia over 36 months on medication. The graph compares three groups: Conjugated Estrogens Alone, Conjugated Estrogens Plus Micronized Progesterone (cyclical), and Placebo Only, with corresponding patient counts at multiple time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.